Key Points
- Mark Goldsmith sold 12,871 shares on March 17 at an average price of $99.48 for $1.28M, cutting his stake by 4.44% to 276,698 shares (worth about $27.5M).
- Several other insiders — including CFO Jack Anders and COO Margaret Horn — also sold shares at roughly $99.48 during the same period, indicating broad insider selling activity.
- The stock trades near $99 with a market cap of $19.7B and 94.34% institutional ownership; analysts maintain a consensus Buy despite a recent EPS miss and an average target price of $78.94 below the current level.
Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) insider Xiaolin Wang sold 2,010 shares of the firm's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $199,954.80. Following the sale, the insider directly owned 116,063 shares of the company's stock, valued at approximately $11,545,947.24. This represents a 1.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Revolution Medicines Price Performance
Shares of NASDAQ:RVMD opened at $98.55 on Friday. The company has a market capitalization of $19.53 billion, a P/E ratio of -16.67 and a beta of 0.99. The company's 50-day moving average is $103.42 and its 200 day moving average is $76.40. The company has a debt-to-equity ratio of 0.16, a quick ratio of 7.14 and a current ratio of 7.14. Revolution Medicines, Inc. has a fifty-two week low of $29.17 and a fifty-two week high of $124.49.
Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($1.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.30). During the same period last year, the firm posted ($1.12) EPS. On average, equities research analysts forecast that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.
Hedge Funds Weigh In On Revolution Medicines
Several hedge funds have recently made changes to their positions in RVMD. General Atlantic L.P. bought a new stake in shares of Revolution Medicines during the 3rd quarter valued at $115,556,000. Norges Bank bought a new position in Revolution Medicines in the 4th quarter worth about $195,568,000. Avoro Capital Advisors LLC purchased a new position in Revolution Medicines during the 4th quarter valued at about $172,840,000. UBS Group AG grew its holdings in Revolution Medicines by 183.6% during the 4th quarter. UBS Group AG now owns 3,087,937 shares of the company's stock valued at $245,954,000 after buying an additional 1,998,972 shares in the last quarter. Finally, Polar Capital Holdings Plc increased its position in shares of Revolution Medicines by 321.2% during the fourth quarter. Polar Capital Holdings Plc now owns 2,013,791 shares of the company's stock valued at $160,398,000 after buying an additional 1,535,686 shares during the period. 94.34% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several research firms recently commented on RVMD. Evercore upgraded Revolution Medicines to a "strong-buy" rating in a research note on Wednesday, February 25th. Wedbush reissued an "outperform" rating on shares of Revolution Medicines in a research report on Friday, January 9th. UBS Group assumed coverage on Revolution Medicines in a research note on Friday, February 27th. They issued a "buy" rating on the stock. Benchmark reaffirmed an "overweight" rating on shares of Revolution Medicines in a research report on Tuesday, February 17th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Revolution Medicines in a report on Thursday, January 22nd. Four equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Revolution Medicines presently has an average rating of "Buy" and a consensus target price of $78.94.
Check Out Our Latest Analysis on RVMD
More Revolution Medicines News
Here are the key news stories impacting Revolution Medicines this week:
- Positive Sentiment: Large institutional buys and heavy institutional ownership (General Atlantic, Norges Bank, Avoro, UBS, Polar Capital and others acquired meaningful stakes or added materially), signaling strong institutional conviction that can support the stock. MarketBeat Institutional/Insider Summary
- Positive Sentiment: Analyst coverage is largely bullish — multiple recent upgrades/initiations (Evercore, Jefferies, UBS, Benchmark) and a consensus “Buy” bias among analysts, which can underpin buying interest and price support. Analyst Coverage Summary
- Neutral Sentiment: Company profile and pipeline: clinical-stage biotech focused on RAS-pathway therapies (RMC-4630, RMC-6291, RMC-6236). Positive long-term potential but clinical/readout risk remains — typical for development-stage biotechs. Company Profile
- Neutral Sentiment: Recent quarterly report (Feb. 25) showed a wider loss (EPS -$1.86) and missed estimates — a reminder of ongoing cash burn and execution risk; analysts expect negative FY EPS. Earnings Summary
- Negative Sentiment: Several senior insiders sold shares on Mar. 17 (large disclosed Form 4s). Mark A. Goldsmith sold 12,871 shares (~$1.28M). SEC filing: Goldsmith SEC Filing
- Negative Sentiment: COO Margaret A. Horn sold 4,583 shares (~$456K). SEC filing: Horn SEC Filing
- Negative Sentiment: Stephen M. Kelsey sold 4,302 shares (~$428K). SEC filing: Kelsey SEC Filing
- Negative Sentiment: CFO Jack Anders sold 2,753 shares (~$274K). SEC filing: Anders SEC Filing
- Negative Sentiment: Insiders Xiaolin Wang and Lin Wei also sold smaller stakes (2,010 and 2,073 shares). SEC filings: Wang SEC Filing · Wei SEC Filing
Revolution Medicines Company Profile
(
Get Free Report)
Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.
The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
